MedMatrix Rx
Daily 340B Morning Briefing
Legal battles and policy debates dominate the 340B landscape. A federal judge decertified 11 clinics from the 340B program, while CMS faces pushback on proposed payment changes. The NASP and major hospital groups submitted comments to CMS, urging revisions to the 2027 Hospital Outpatient Prospective Payment System rule. Meanwhile, the HRSA’s revised 340B Rebate Model Pilot Program is set to launch in 2027, sparking further discussion on its implications.
EXECUTIVE SUMMARY
01
Federal judge decertifies 11 clinics from 340B program.
A U.S. District Court judge in D.C. decertified 11 clinics, finding they failed to meet statutory 340B requirements.
A U.S. District Court judge in D.C. decertified 11 clinics, finding they failed to meet statutory 340B requirements.
Source: Becker’s Hospital Review
02
NASP comments on CMS’ proposed 340B payment changes.
NASP submitted comments on CMS’ CY 2027 HOPPS proposed rule, focusing on Medicare reimbursement changes for 340B drugs.
NASP submitted comments on CMS’ CY 2027 HOPPS proposed rule, focusing on Medicare reimbursement changes for 340B drugs.
Source: NASP
03
Milwaukee hospital sues CVS over $18M 340B diversion.
Froedtert Memorial Lutheran Hospital alleges CVS diverted $18 million in 340B savings, filing suit in E.D. Wisconsin.
Froedtert Memorial Lutheran Hospital alleges CVS diverted $18 million in 340B savings, filing suit in E.D. Wisconsin.
Source: Becker’s Hospital Review
04
Hospital groups urge CMS to revise 2027 outpatient rule.
AHA, AAMC, and AMGA urged CMS to withdraw or revise key provisions of the CY 2027 HOPPS proposed rule.
AHA, AAMC, and AMGA urged CMS to withdraw or revise key provisions of the CY 2027 HOPPS proposed rule.
Source: Becker’s Hospital Review
05
HRSA to launch revised 340B Rebate Model Pilot Program.
HRSA’s revised 340B Rebate Model Pilot Program will launch on January 1, 2027, focusing on MFP and 340B ceiling price conflicts.
HRSA’s revised 340B Rebate Model Pilot Program will launch on January 1, 2027, focusing on MFP and 340B ceiling price conflicts.
Source: Drug Channels
06
AHA opposes CMS’ 340B payment clawback proposal.
AHA urged CMS not to finalize proposals that would accelerate a 340B payment clawback and cut drug reimbursement rates.
AHA urged CMS not to finalize proposals that would accelerate a 340B payment clawback and cut drug reimbursement rates.
Source: Becker’s Hospital Review
07
AstraZeneca challenges Illinois’ 340B law in court.
AstraZeneca filed a lawsuit against Illinois’ 340B contract pharmacy law, arguing it violates federal law.
AstraZeneca filed a lawsuit against Illinois’ 340B contract pharmacy law, arguing it violates federal law.
Source: Becker’s Hospital Review
08
AAMC and AHA push for changes in 340B-related provisions.
AAMC and AHA submitted letters to CMS and Congress seeking changes to 340B-related provisions in proposed rules and legislation.
AAMC and AHA submitted letters to CMS and Congress seeking changes to 340B-related provisions in proposed rules and legislation.
Source: Becker’s Hospital Review
09
AbbVie lawsuit sees intervention from 340B groups.
A D.C. federal judge allowed 340B Health and other groups to intervene in AbbVie’s lawsuit over 340B issues.
A D.C. federal judge allowed 340B Health and other groups to intervene in AbbVie’s lawsuit over 340B issues.
Source: Becker’s Hospital Review
10
CMS faces pushback on 340B rebate model from hospitals.
Hospitals are urging CMS to require upfront negotiated drug prices instead of retrospective rebates in the Medicare Drug Price Negotiation Program.
Hospitals are urging CMS to require upfront negotiated drug prices instead of retrospective rebates in the Medicare Drug Price Negotiation Program.
Source: Becker’s Hospital Review
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The decertification of 11 clinics from the 340B program highlights significant compliance challenges and may lead to increased scrutiny of other participating entities. This decision could set a precedent for future cases, potentially impacting the operational and financial stability of clinics relying on 340B savings.
Emerging risks.
- The decertification of clinics could lead to increased audits and compliance checks across the 340B program.
- Hospitals face financial strain from CMS’ proposed 340B payment clawback, risking service cuts.
- Legal challenges to state 340B laws may result in regulatory uncertainty and operational disruptions.
- Retrospective rebate models could complicate financial planning for hospitals relying on 340B savings.
Emerging opportunities.
- Hospitals can advocate for policy changes to ensure fair 340B reimbursement practices.
- Entities may explore partnerships to strengthen compliance and mitigate risks of decertification.
- The launch of the 340B Rebate Model Pilot Program offers a chance to test new reimbursement methodologies.
- Stakeholders can engage with CMS during comment periods to influence future 340B regulations.
Key actions for providers.
- Review and strengthen compliance protocols to meet 340B program requirements.
- Engage in advocacy efforts to influence CMS policies on 340B reimbursement.
- Monitor legal developments in state and federal courts affecting 340B regulations.
- Prepare for potential financial impacts from CMS’ proposed payment changes and rebate models.
TOP STORIES
Federal judge decertifies 11 clinics from 340B program.
Becker’s Hospital Review · August 20, 2026
- A federal judge in D.C. decertified 11 clinics for failing 340B statutory requirements.
- The clinics received funding through Sagebrush Health Services, not directly from government.
- The decision affects clinics in Nevada with active certifications as recently as 2025.
NASP comments on CMS’ proposed 340B payment changes.
NASP · September 1, 2026
- NASP submitted comments on CMS’ CY 2027 HOPPS proposed rule.
- The comments focus on Medicare reimbursement changes for 340B-acquired drugs.
- NASP addresses operational and compliance considerations for 340B program administration.
Milwaukee hospital sues CVS over $18M 340B diversion.
Becker’s Hospital Review · August 31, 2026
- Froedtert Memorial Lutheran Hospital alleges CVS diverted $18 million in 340B savings.
- The suit was filed in U.S. District Court for the Eastern District of Wisconsin.
- CVS and its subsidiaries are accused of lowering reimbursements post-claim adjudication.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
Hospital groups urge CMS to revise 2027 outpatient rule.
Becker’s Hospital Review · August 31, 2026
- AHA, AAMC, and AMGA submitted comments to CMS on the CY 2027 HOPPS proposed rule.
- The groups oppose 340B drug payment cuts and site-neutral payment expansion.
- They argue the proposed 2.4% net payment update is insufficient for hospitals.
HRSA to launch revised 340B Rebate Model Pilot Program.
Drug Channels · August 25, 2026
- HRSA’s revised 340B Rebate Model Pilot Program launches January 1, 2027.
- The pilot focuses on MFP and 340B ceiling price conflicts.
- The program is limited to 2026-2027 MFP drugs, representing less than 5.5% of 340B sales.
AHA opposes CMS’ 340B payment clawback proposal.
Becker’s Hospital Review · August 26, 2026
- AHA urged CMS not to finalize a proposal accelerating 340B payment clawbacks.
- The proposal would increase hospital repayments from 0.5% to 3% annually.
- Over 500 hospitals could face repayments exceeding $1 million each year.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| E.D. Wis. | Froedtert Memorial Lutheran Hospital Inc v. CVS Health Corporation [source] | August 20, 2026 |
| N.D. Ill. | ASTRAZENECA PHARMACEUTICALS LP v. KWAME RAOUL, in his official capacity as ATTORNEY GENERAL of the STATE OF ILLINOIS [source] | August 14, 2026 |
| D. Maryland | State of New York v. U.S. Department of Health and Human Services [source] | August 27, 2026 |
| D.C. | AbbVie Inc. v. Kennedy, 1:26-cv-1190-RDM, filed 2026-08-24. [source] | August 24, 2026 |
SOCIAL MEDIA & STAKEHOLDER SENTIMENT
The following items were identified through web searches for recent stakeholder and social commentary on the U.S. 340B Drug Pricing Program from the past 90 days, including reactions, statements, op-eds, and advocacy positions from various organizations and platforms.
AHA Feedback Re: the 340B for Patients Act Discussion Draft
American Hospital Association (AHA) · August 25, 2026
- Main theme: AHA’s response to proposed changes in the 340B program
- Stakeholder sentiment: The AHA expresses concern over proposed changes, stating that the rebate model would create significant cash-flow challenges for hospitals, particularly rural and safety-net providers.
- Potential implications: Potential financial strain on hospitals, especially those serving underserved communities.
- Credibility: The AHA is a reputable organization representing hospitals and health systems.
Why Pharma And Hospitals Are At Odds Over The 340B Program
Forbes · June 16, 2026
- Main theme: Analysis of the conflict between pharmaceutical companies and hospitals over the 340B program
- Stakeholder sentiment: The article highlights the tension between pharmaceutical companies and hospitals, noting that manufacturers argue the program encourages hospitals to favor higher-priced drugs, while hospitals defend the program as vital for supporting safety-net providers.
- Potential implications: Ongoing policy debates and potential reforms to the 340B program.
- Credibility: Forbes is a well-established business and financial news outlet.
The 340B Drug Pricing Program and Community Health Centers: A Review of Literature
Advocacy for Community Health (Substack) · July 2026
- Main theme: Review of literature on the 340B program’s impact on community health centers
- Stakeholder sentiment: The review discusses both benefits and criticisms of the program, including concerns about contract pharmacy arrangements and transparency in the use of program savings.
- Potential implications: Potential policy changes and increased scrutiny of the program’s operations.
- Credibility: Substack is a platform for independent writers; the credibility depends on the author’s expertise.
WHAT TO WATCH NEXT
- HRSA’s revised 340B Rebate Model Pilot Program launches January 1, 2027. [source]
- CMS’ final decision on the CY 2027 HOPPS proposed rule is expected soon. [source]
- Court rulings on AstraZeneca’s and AbbVie’s lawsuits against Illinois’ 340B law are pending. [source]
- Monitor the impact of the decertification of 11 clinics on other 340B participants. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.